Abstract
Aspirin is in many ways a non- steroidal anti-inflammatory drug (NSAID) prototype. Similar to conventional NSAIDs the gastric side effects of aspirin are well studied. However its potential adverse effects on the small and large intestine are less well known and under- researched.
Experimental studies support a pathogenic pathway leading to NSAID enteropathy involving the topical effects on the intestinal barrier (mucous layer, enterocytes) that lead to dysfunction and increased intestinal permeability followed by increased exposure to luminal triggers and acute inflammation. Although aspirin has a toxic effect in vitro, enteral or parenteral administration in vivo, in animal models, did not result to intestinal injury.
In man, experimental studies have revealed changes in intestinal permeability similar to conventional NSAIDs but of lesser magnitude. The clinical implication of these changes though is not known. Population studies have associated aspirin use with occult gastrointestinal bleeding from the small or large bowel although the magnitude of this risk is difficult to estimate but certainly small. Associations to colitis flare-ups have been made in case reports and retrospective cohort studies but low dose aspirin appears safe. Complications of diverticular disease may also be more frequent with aspirin use.
Keywords: Aspirin, small intestine, large intestine, enteropathy, adverse events.
Current Pharmaceutical Design
Title:Aspirin Induced Adverse Effects on the Small and Large Intestine
Volume: 21 Issue: 35
Author(s): Polychronis Pavlidis and Ingvar Bjarnason
Affiliation:
Keywords: Aspirin, small intestine, large intestine, enteropathy, adverse events.
Abstract: Aspirin is in many ways a non- steroidal anti-inflammatory drug (NSAID) prototype. Similar to conventional NSAIDs the gastric side effects of aspirin are well studied. However its potential adverse effects on the small and large intestine are less well known and under- researched.
Experimental studies support a pathogenic pathway leading to NSAID enteropathy involving the topical effects on the intestinal barrier (mucous layer, enterocytes) that lead to dysfunction and increased intestinal permeability followed by increased exposure to luminal triggers and acute inflammation. Although aspirin has a toxic effect in vitro, enteral or parenteral administration in vivo, in animal models, did not result to intestinal injury.
In man, experimental studies have revealed changes in intestinal permeability similar to conventional NSAIDs but of lesser magnitude. The clinical implication of these changes though is not known. Population studies have associated aspirin use with occult gastrointestinal bleeding from the small or large bowel although the magnitude of this risk is difficult to estimate but certainly small. Associations to colitis flare-ups have been made in case reports and retrospective cohort studies but low dose aspirin appears safe. Complications of diverticular disease may also be more frequent with aspirin use.
Export Options
About this article
Cite this article as:
Pavlidis Polychronis and Bjarnason Ingvar, Aspirin Induced Adverse Effects on the Small and Large Intestine, Current Pharmaceutical Design 2015; 21 (35) . https://dx.doi.org/10.2174/1381612821666150915110058
DOI https://dx.doi.org/10.2174/1381612821666150915110058 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Drugs Targeting Atherosclerosis: Current and Emerging Approaches (Executive Editors: Vangelis G. Manolopoulos and Anna Tavridou)]
Current Pharmaceutical Design Helicobacter Pylori Infection, Immune Response and Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Medicinal Plants in the Treatment of Peptic Ulcer Disease: A Review
Mini-Reviews in Medicinal Chemistry Advances in Fish Cytokine Biology Give Clues to the Evolution of a Complex Network
Current Pharmaceutical Design Hybrid Viral Vectors for Vaccine and Antibody Production in Plants
Current Pharmaceutical Design The Role of Transforming Growth Factor β1 in the Regulation of Blood Pressure
Current Hypertension Reviews Down Regulated Expression of Claudin-1 and Claudin-5 and Up Regulation of β-Catenin: Association with Human Glioma Progression
CNS & Neurological Disorders - Drug Targets New Therapeutic Approaches by Using Microorganism-Derived Compounds
Current Medicinal Chemistry Vaccines For Type 1 Diabetes: Prevention or Reversal?
Current Diabetes Reviews Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design Illuminating microRNA Transcription from the Epigenome
Current Genomics Engineered Nanoparticles with Antimicrobial Property
Current Drug Metabolism Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Endogenous Factors in the Recovery of Reproductive Function After Testicular Injury and Cancer
Current Molecular Medicine Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry Neuroimmune Dysregulation in Prepubertal and Adolescent Individuals Affected by Klinefelter Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Evaluation of Ocular Irritation and Bioavailability of Voriconazole Loaded Microemulsion
Current Drug Delivery Insoluble Solids in Brazilian and Floridian Acai (Euterpe oleraceae Mart.)
The Natural Products Journal Oral Immune Regulation: A New Mode of Therapy Against Chronic Viral Infections
Recent Patents on Anti-Infective Drug Discovery Mesenchymal Stem Cells: A Potent Cell Source for COVID-19
Coronaviruses